TY - JOUR
T1 - Associations of β-Amyloid and Vascular Burden with Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort
AU - Keuss, Sarah E.
AU - Coath, William
AU - Nicholas, Jennifer M.
AU - Poole, Teresa
AU - Barnes, Josephine
AU - Cash, David M.
AU - Lane, Christopher A.
AU - Parker, Thomas D.
AU - Keshavan, Ashvini
AU - Buchanan, Sarah M.
AU - Wagen, Aaron Z.
AU - Storey, Mathew
AU - Harris, Matthew
AU - Malone, Ian B.
AU - Sudre, Carole H.
AU - Lu, Kirsty
AU - James, Sarah-Naomi
AU - Street, Rebecca
AU - Thomas, David L.
AU - Dickson, John C.
AU - Murray-Smith, Heidi
AU - Wong, Andrew
AU - Freiberger, Tamar
AU - Crutch, Sebastian
AU - Richards, Marcus
AU - Fox, Nick C.
AU - Schott, Jonathan M.
N1 - Funding Information:
S.E. Keuss, W. Coath, J.M. Nicholas, and T Poole report no disclosures relevant to the manuscript. J. Barnes was funded by an Alzheimer's Research UK Senior Fellowship (ARUK-SRF2016A-2). D.M. Cash was supported by Alzheimer's Research UK (ARUK-PG2017-1946), the UCL/UCLH National Institute of Health and Care Research Biomedical Research Centre, and the UK Dementia Research Institute, which is funded by the UK Medical Research Council, Alzheimer’s Society, and Alzheimer’s Research UK. C.A. Lane is a full-time employee of Roche Products Ltd and a shareholder in F. Hoffmann-La Roche Ltd. T.D. Parker has received support from a Wellcome Trust Clinical Research Fellowship and a UK National Institute of Health and Care Research academic clinical lectureship. A. Keshavan was supported by a Wolfson Clinical Research Fellowship and a Weston Brain Institute and Selfridges Group Foundation award (UB170045). S.M. Buchanan reports no disclosures relevant to the manuscript. A.Z. Wagen is funded by a Wolfson Clinical Research Fellowship. M. Storey, M. Harris, and I. B. Malone report no disclosures relevant to the manuscript. C.H. Sudre was supported by the Alzheimer's Society Junior Fellowship (AS-JF-17–011). K. Lu, S.-N. James, and R. Street report no disclosures relevant to this manuscript. D.L. Thomas is funded by the Leonard Wolfson Experimental Neurology Centre and University College London Hospitals Biomedical Research Centre. J.C. Dickson has received payment for consultancy on the running of multicenter studies from Biogen, Bioclinica, and GE Healthcare, and he is supported by the National Institute for Health Research, University College London Hospitals Biomedical Research Centre. H. Murray-Smith reports no disclosures relevant to this manuscript. A. Wong is funded by the Medical Research Council (MC_UU_00,019/1, MC_UU_00,019/3). T. Freiberger reports no disclosures relevant to the manuscript. S. Crutch is supported by an Alzheimer's Research UK Senior Research Fellowship (ARUK-SRF2013-8). M. Richards is funded by the Medical Research Council (MC_UU_12,019/1, MC_UU_12,019/3). N.C. Fox has served as a consultant, on advisory boards, or on a data monitoring committee for Roche, Biogen, and Ionis, and he acknowledges support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre, Rosetrees Trust, Alzheimer’s Research UK, and the UK Dementia Research Institute. J.M. Schott has received research funding from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche Pharmaceuticals, Biogen, Merck, and Eli Lilly; has given educational lectures sponsored by GE Healthcare, Eli Lilly, and Biogen; serves on a Data Safety Monitoring Committee for Axon Neuroscience SE; and is supported by University College London Hospitals Biomedical Research Centre, Engineering and Physical Sciences Research Council (EP/J020990/1), British Heart Foundation (PG/17/90/33,415), and EU’s Horizon 2020 Research and Innovation Programme (666,992). Go to Neurology.org/N for full disclosures.
Funding Information:
The Article Processing Charge was funded by Medical Research Council.
Funding Information:
Insight 46 is funded by grants from Alzheimer's Research UK (ARUK-PG2014-1946, ARUK-PG2017-1946 principal investigators [PIs] Schott, Fox, Richards), Alzheimer's Association (SG-666374-UK BIRTH COHORT PI Schott), the Medical Research Council Dementias Platform UK (CSUB19166 PIs Schott, Fox, Richards), The Wolfson Foundation (PR/ylr/18575 PIs Fox, Schott), The Medical Research Council (MC-UU-12019/1 PI Kuh and MC-UU-12019/3 PI Richards), Selfridges Group Foundation (22/3/18 PIs Schott, Keshavan), and Brain Research Trust (UCC14191, PI Schott). This research was funded in whole or in part by the Wellcome Trust (Clinical Research Fellowship 200109/Z/15/Z Parker).
Publisher Copyright:
© 2022 American Academy of Neurology.
PY - 2022/7/12
Y1 - 2022/7/12
N2 - Background and ObjectivesThe goals of this work were to quantify the independent and interactive associations of β-amyloid (Aβ) and white matter hyperintensity volume (WMHV), a marker of presumed cerebrovascular disease (CVD), with rates of neurodegeneration and to examine the contributions of APOE ϵ4 and vascular risk measured at different stages of adulthood in cognitively normal members of the 1946 British Birth Cohort.MethodsParticipants underwent brain MRI and florbetapir-Aβ PET as part of Insight 46, an observational population-based study. Changes in whole-brain, ventricular, and hippocampal volume were directly measured from baseline and repeat volumetric T1 MRI with the boundary shift integral. Linear regression was used to test associations with baseline Aβ deposition, baseline WMHV, APOE ϵ4, and office-based Framingham Heart Study Cardiovascular Risk Score (FHS-CVS) and systolic blood pressure (BP) at ages 36, 53, and 69 years.ResultsThree hundred forty-six cognitively normal participants (mean [SD] age at baseline scan 70.5 [0.6] years; 48% female) had high-quality T1 MRI data from both time points (mean [SD] scan interval 2.4 [0.2] years). Being Aβ positive at baseline was associated with 0.87-mL/y faster whole-brain atrophy (95% CI 0.03, 1.72), 0.39-mL/y greater ventricular expansion (95% CI 0.16, 0.64), and 0.016-mL/y faster hippocampal atrophy (95% CI 0.004, 0.027), while each 10-mL additional WMHV at baseline was associated with 1.07-mL/y faster whole-brain atrophy (95% CI 0.47, 1.67), 0.31-mL/y greater ventricular expansion (95% CI 0.13, 0.60), and 0.014-mL/y faster hippocampal atrophy (95% CI 0.006, 0.022). These contributions were independent, and there was no evidence that Aβ and WMHV interacted in their effects. There were no independent associations of APOE ϵ4 with rates of neurodegeneration after adjustment for Aβ status and WMHV, no clear relationships between FHS-CVS or systolic BP and rates of neurodegeneration when assessed across the whole sample, and no evidence that FHS-CVS or systolic BP acted synergistically with Aβ.DiscussionAβ and presumed CVD have distinct and additive effects on rates of neurodegeneration in cognitively normal elderly. These findings have implications for the use of MRI measures as biomarkers of neurodegeneration and emphasize the importance of risk management and early intervention targeting both pathways.
AB - Background and ObjectivesThe goals of this work were to quantify the independent and interactive associations of β-amyloid (Aβ) and white matter hyperintensity volume (WMHV), a marker of presumed cerebrovascular disease (CVD), with rates of neurodegeneration and to examine the contributions of APOE ϵ4 and vascular risk measured at different stages of adulthood in cognitively normal members of the 1946 British Birth Cohort.MethodsParticipants underwent brain MRI and florbetapir-Aβ PET as part of Insight 46, an observational population-based study. Changes in whole-brain, ventricular, and hippocampal volume were directly measured from baseline and repeat volumetric T1 MRI with the boundary shift integral. Linear regression was used to test associations with baseline Aβ deposition, baseline WMHV, APOE ϵ4, and office-based Framingham Heart Study Cardiovascular Risk Score (FHS-CVS) and systolic blood pressure (BP) at ages 36, 53, and 69 years.ResultsThree hundred forty-six cognitively normal participants (mean [SD] age at baseline scan 70.5 [0.6] years; 48% female) had high-quality T1 MRI data from both time points (mean [SD] scan interval 2.4 [0.2] years). Being Aβ positive at baseline was associated with 0.87-mL/y faster whole-brain atrophy (95% CI 0.03, 1.72), 0.39-mL/y greater ventricular expansion (95% CI 0.16, 0.64), and 0.016-mL/y faster hippocampal atrophy (95% CI 0.004, 0.027), while each 10-mL additional WMHV at baseline was associated with 1.07-mL/y faster whole-brain atrophy (95% CI 0.47, 1.67), 0.31-mL/y greater ventricular expansion (95% CI 0.13, 0.60), and 0.014-mL/y faster hippocampal atrophy (95% CI 0.006, 0.022). These contributions were independent, and there was no evidence that Aβ and WMHV interacted in their effects. There were no independent associations of APOE ϵ4 with rates of neurodegeneration after adjustment for Aβ status and WMHV, no clear relationships between FHS-CVS or systolic BP and rates of neurodegeneration when assessed across the whole sample, and no evidence that FHS-CVS or systolic BP acted synergistically with Aβ.DiscussionAβ and presumed CVD have distinct and additive effects on rates of neurodegeneration in cognitively normal elderly. These findings have implications for the use of MRI measures as biomarkers of neurodegeneration and emphasize the importance of risk management and early intervention targeting both pathways.
UR - http://www.scopus.com/inward/record.url?scp=85134269872&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000200524
DO - 10.1212/WNL.0000000000200524
M3 - Article
C2 - 35410910
SN - 0028-3878
VL - 99
SP - E129-E141
JO - Neurology
JF - Neurology
IS - 2
ER -